American Journal of Cardiovascular Drugs

, Volume 1, Issue 1, pp 45–50 | Cite as

Current Management of Acute Symptomatic Deep Vein Thrombosis

  • John A. Heit
Therapy in Practice

Abstract

Venous thromboembolism is a common and potentially fatal disease. If properly used, anticoagulation therapy is effective in preventing recurrence of venous thromboembolism and in improving survival. Symptomatic patients with an objective diagnosis of acute deep vein thrombosis (DVT) or pulmonary embolism (PE) should receive immediate systemic heparin anticoagulation at dosages sufficient to rapidly prolong the activated partial thromboplastin time into the laboratory-specific therapeutic range; this range corresponds to a plasma heparin concentration of 0.2 to 0.4 IU/ml (as measured by protamine sulfate titration), or 0.3 to 0.7 anti-Xa IU/ml. An oral vitamin K antagonist (e.g. warfarin) should be started within 24 hours after starting heparin; the starting dose should be the estimated patient-specific daily dose with no loading dose. Heparin and warfarin anticoagulation should be overlapped for at least 4 to 5 days and until the international normalized ratio (INR) is within the therapeutic range (2.0 to 3.0) on 2 measurements made at least 24 hours apart.

The duration of warfarin anticoagulation should be individualized based on the respective risks of venous thromboembolism recurrence and anticoagulant-related bleeding. In general, warfarin should be continued for at least 3 months, and longer for patients with recurrent or idiopathic venous thromboembolism, malignant neoplasm, neurologic disease with extremity paresis, obesity, or laboratory evidence of a lupus anticoagulant/anticardiolipin antibody, homozygous carrier or combined heterozygous carrier for the factor V R506Q (Leiden) and prothrombin G20210A mutations, and possibly deficiency of either antithrombin, protein C, or protein S.

Low molecular weight heparin (LMWH) is effective and well tolerated as acute therapy for patients with DVT or stable PE, and does not require laboratory monitoring or dose adjustment. Outpatient LMWH therapy is also well tolerated and cost effective for most patients with DVT, and possibly for selected patients with PE.

References

  1. 1.
    Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998; 158: 585–93PubMedCrossRefGoogle Scholar
  2. 2.
    Heit JA, Silverstein MD, Mohr DN, et al. Predictors of survival after deep vein thrombosis and pulmonary embolism. Arch Intern Med 1999; 159: 445–53PubMedCrossRefGoogle Scholar
  3. 3.
    Heit JA, Mohr DN, Silverstein MD, et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 2000; 160: 761–8PubMedCrossRefGoogle Scholar
  4. 4.
    Hyers TM, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 1998 Nov; 114 (5 Suppl.): 561S–78SPubMedCrossRefGoogle Scholar
  5. 5.
    Brandjes CPM, Heijboer H, Buller HR, et al. Acenocoumarol and heparin compared to acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med 1992; 327: 1485–9PubMedCrossRefGoogle Scholar
  6. 6.
    Hellemans J, Vorlat M, Verstraete M. Survival time of prothrombin and factors VII, IX, and X after completely synthesis blocking doses of coumarin derivatives. Br J Haematol 1963; 9: 506–12PubMedCrossRefGoogle Scholar
  7. 7.
    Zivelin A, Rao LVM, Rapaport SI. Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual procoagulant vitamin K-dependent clotting factors. J Clin Invest 1993; 92: 2131–40PubMedCrossRefGoogle Scholar
  8. 8.
    Heit JA, Stewart ML, Owen WG. The role of plasma prothrombin activity in the acute thrombotic response to severe arterial injury. Thromb Haemost 1995; 73: 1341Google Scholar
  9. 9.
    Hull RD, Raskob GE, Brant RF, et al. Relationship between time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Arch Intern Med 1997; 157: 2562–8PubMedCrossRefGoogle Scholar
  10. 10.
    Hull RD, Rascob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal vein thrombosis. N Engl J Med 1986; 315: 1109–14PubMedCrossRefGoogle Scholar
  11. 11.
    Cruickshank MK, Levine MN, Hirsh J, et al. A standard heparin nomogram for the management of heparin therapy. Arch Intern Med 1991; 151: 333–7PubMedCrossRefGoogle Scholar
  12. 12.
    Raschke RA, Reilly BM, Guidry JR, et al. The weight-based dosing nomogram compared with a standard care nomogram. Ann Intern Med 1993; 119: 874–81PubMedGoogle Scholar
  13. 13.
    Anand S, Ginsberg J, Kearon C, et al. The relationship between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin. Arch Intern Med 1996; 156: 1677–81PubMedCrossRefGoogle Scholar
  14. 14.
    Brill-Edwards P, Ginsberg JS, Johnston M, et al. Establishing a therapeutic range of heparin therapy. Ann Intern Med 1993; 119: 104–9PubMedGoogle Scholar
  15. 15.
    Hirsh J, Warkentin TE, Raschke R, et al. Heparin and low-molecular-weight heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998; 114 (5 Suppl.): 489S–510SPubMedCrossRefGoogle Scholar
  16. 16.
    Young E, Prins M, Levine M, et al. Heparin binding to plasma proteins, and important mechanism for heparin resistance. Thromb Haemost 1992; 67: 639–43PubMedGoogle Scholar
  17. 17.
    Kraaigenhagen RA, in’t Anker PS, Koopman MMW, et al. High plasma concentration of Factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost 2000; 83: 5–9Google Scholar
  18. 18.
    Kyrle PA, Minar E, Hirschl M, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 2000; 343:457–62PubMedCrossRefGoogle Scholar
  19. 19.
    Levine MN, Hirsh J, Gent M, et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 1995; 74: 606–11PubMedGoogle Scholar
  20. 20.
    Levine MN, Hirsh J, Gent M, et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 1994; 154: 49–56PubMedCrossRefGoogle Scholar
  21. 21.
    Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992; 79: 1–17PubMedGoogle Scholar
  22. 22.
    Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337: 688–98PubMedCrossRefGoogle Scholar
  23. 23.
    Young E, Wells PS, Holloway S, et al. Ex-vivo and in-vivo evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb Haemost 1994; 71: 300–4PubMedGoogle Scholar
  24. 24.
    Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992; 326: 975–83PubMedCrossRefGoogle Scholar
  25. 25.
    Prandoni P, Lensing AW, Buller HR, et al. Comparison of subcutaneous low-molecular weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992; 339: 441–5PubMedCrossRefGoogle Scholar
  26. 26.
    Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin. N Engl J Med 1995; 332: 1330–5PubMedCrossRefGoogle Scholar
  27. 27.
    Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334: 677–81PubMedCrossRefGoogle Scholar
  28. 28.
    Koopman MMW, Prandoni P, Piovelli F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular weight heparin administered at home. N Engl J Med 1996; 334: 682–7PubMedCrossRefGoogle Scholar
  29. 29.
    Simonneau G, Sors H, Charbonnier B, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. N Engl J Med 1997; 337: 663–9PubMedCrossRefGoogle Scholar
  30. 30.
    The Columbus Investigators. Low-molecular weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997; 337: 657–62CrossRefGoogle Scholar
  31. 31.
    Wells PS, Kovacs MJ, Bormanis J, et al. Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin: a comparison of patient self-injection with homecare injection. Arch Intern Med 1998; 158: 1809–12PubMedCrossRefGoogle Scholar
  32. 32.
    Brandjes DPM, Büller HR, Heijboer H, et al. Randomized trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet 1997; 349: 759–62PubMedCrossRefGoogle Scholar
  33. 33.
    Lindmarker P, Holmstrom H. Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis: a feasibility and health economic study in an outpatient setting. J Intern Med 1996; 240: 395–401PubMedCrossRefGoogle Scholar
  34. 34.
    Fiessinger JN, Lopez-Fernandez M, Gatterer E, et al. Once daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. Thromb Haemost 1996; 76: 195–9PubMedGoogle Scholar
  35. 35.
    van der Heijden JF, Prins MH, Büller, HR. For the initial treatment of venous thromboembolism: are all low-molecular-weight heparin compounds the same? Thromb Res 2000; 100: V121–30PubMedCrossRefGoogle Scholar
  36. 36.
    Gould MK, Dembitzer AD, Sanders G, et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: a cost-effectiveness analysis. Ann Intern Med 1999; 130: 789–99PubMedGoogle Scholar
  37. 37.
    Hull RD, Raskob GE, Rosenbloom D, et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990; 322: 1260–4PubMedCrossRefGoogle Scholar
  38. 38.
    White RH, Zhou H, Romano PS. Length of hospital stay for treatment of deep venous thrombosis and the incidence of recurrent thromboembolism. Arch Intern Med 1998; 158: 1005–10PubMedCrossRefGoogle Scholar
  39. 39.
    Godal HC, Madsen K, Nissen-Meyer R. Thrombo-embolism in patients with total proconvertin (factor VII) deficiency: a report of two cases. Acta Med Scand 1962; 171: 325–7PubMedCrossRefGoogle Scholar
  40. 40.
    Greshwin ME, Gude JK. Deep vein thrombosis and pulmonary embolism in congenital factor VII deficiency. N Engl J Med 1973; 288: 141–2CrossRefGoogle Scholar
  41. 41.
    Harrison L, Johnston M, Massicotte MP, et al. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med 1997; 126: 133–6PubMedGoogle Scholar
  42. 42.
    Schulman S, Rhedin A-S, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995; 332: 1661–5PubMedCrossRefGoogle Scholar
  43. 43.
    Schulman S, Granqvist S, Holmstrom M, et al. The duration of oral anticoagulation therapy after a second episode of venous thromboembolism. N Engl J Med 1997; 336: 393–8PubMedCrossRefGoogle Scholar
  44. 44.
    Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340: 901–7PubMedCrossRefGoogle Scholar
  45. 45.
    Schulman S, Svenungsson E, Granqvist S, et al. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Am J Med 1998; 104: 332–8PubMedCrossRefGoogle Scholar
  46. 46.
    De Stefano V, Martinelli I, Mannucci PM, et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med 1999; 341: 801–6PubMedCrossRefGoogle Scholar
  47. 47.
    De Stefano V, Finazzi G, Mannucci PM. Inherited thrombophilia: pathogenesis, clinical syndromes and management. Blood 1996; 87 (9): 3531–44PubMedGoogle Scholar
  48. 48.
    Lane DA, Mannucci PM, Bauer KA, et al. Inherited thrombophilia: part 1. Thromb Haemost 1996; 76 (5): 651–62PubMedGoogle Scholar
  49. 49.
    Lane DA, Mannucci PM, Bauer KA, et al. Inherited thrombophilia: part 2. Thromb Haemost 1996; 76 (6): 824–34PubMedGoogle Scholar
  50. 50.
    Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood 2000; 95: 1517–32PubMedGoogle Scholar

Copyright information

© Adis International Limited 2001

Authors and Affiliations

  • John A. Heit
    • 1
  1. 1.Division of Cardiovascular Diseases, Section of Vascular Diseases, and the Division of Hematology, Section of Hematology Research, Department of Internal Medicine, Plummer 549Mayo Clinic and FoundationRochesterUSA

Personalised recommendations